Your search for evid returned 4541 results

Class I study shows single doses of aducanumab safe, well tolerated; class II studies show reduced amyloid deposition on brain PET at one year

Limited evidence suggests that continuing biological DMARDs may lower risk for disease flares without increasing risk for postop complications

Evidence currently inadequate for assessing the balance of benefits and harms of screening for atrial fibrillation in asymptomatic adults

Current evidence is inadequate for assessing benefits and harms of type 2 diabetes screening in children and adolescents

Specific retinal conditions proportionately more common for PPS users versus users of other interstitial cystitis, bladder pain drugs

Current evidence is insufficient for assessing the balance of benefits and harms of screening asymptomatic ≥65s in primary care setting

Current evidence is insufficient for assessing the balance of benefits and harms of screening adults without signs or symptoms of glaucoma

Evidence insufficient to evaluate the benefits and harms of screening for eating disorders in adolescents and adults

In seven of 22 cases, approval used new interpretations of original evidence and did not require new evidence

The analysis included 5 antiseizure medications (eslicarbazepine, perampanel, brivaracetam, cannabidiol, and cenobamate) evaluated in 17 randomized clinical trials.